Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

LON D LYNN

Allopathic & Osteopathic Physicians Family Medicine

NPI
1497898282
CMS profile
204601
Location
TAMPA, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$2,741.69

24 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Travel and Lodging $1,994.13 13
Food and Beverage $747.56 11

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
Eli Lilly and Company $1,587.85 15
Pacira Pharmaceuticals Incorporated $1,122.50 8
GENZYME CORPORATION $31.34 1

Page 1 of 1; records 1–24 of 24 matching records. This page contains 24 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

LON D LYNN

NPI 1497898282 · CMS profile ID 204601

Allopathic & Osteopathic Physicians / Family Medicine

TAMPA, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–24 of 24 matching records. This page contains 24 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1497898282?year=2024&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
LON D LYNN, NPI 1497898282, CMS profile ID 204601. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–24 of 24 matching records. This page contains 24 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1497898282?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). LON D LYNN, NPI 1497898282, CMS profile ID 204601. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–24 of 24 matching records. This page contains 24 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1497898282?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
LON D LYNN, NPI 1497898282, CMS profile ID 204601, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–24 of 24 matching records. This page contains 24 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1497898282?year=2024&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

24 matching records · $2,741.69 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 24 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–24 of 24.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Eli Lilly and Company $14.9906/17/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135092865 CMS
Eli Lilly and Company $103.5806/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135092867 CMS
Eli Lilly and Company $28.2406/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135136804 CMS
Eli Lilly and Company $320.0006/17/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135138986 CMS
Eli Lilly and Company $339.0006/17/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135146480 CMS
Eli Lilly and Company $42.9806/17/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135146482 CMS
Eli Lilly and Company $17.5006/17/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135146484 CMS
Eli Lilly and Company $65.9206/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135146486 CMS
Eli Lilly and Company $32.0006/17/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135146488 CMS
Eli Lilly and Company $102.0206/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135156201 CMS
Eli Lilly and Company $65.9206/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135156203 CMS
Eli Lilly and Company $237.4606/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135157457 CMS
Eli Lilly and Company $175.0006/17/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135157459 CMS
Eli Lilly and Company $28.2406/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135158081 CMS
Eli Lilly and Company $15.0006/17/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135158083 CMS
GENZYME CORPORATION $31.3404/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139580856 CMS
Pacira Pharmaceuticals Incorporated $24.0001/13/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151252183 CMS
Pacira Pharmaceuticals Incorporated $161.3501/13/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151252185 CMS
Pacira Pharmaceuticals Incorporated $828.9701/13/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151252187 CMS
Pacira Pharmaceuticals Incorporated $20.4601/13/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151252189 CMS
Pacira Pharmaceuticals Incorporated $48.5001/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151252191 CMS
Pacira Pharmaceuticals Incorporated $11.0301/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151252193 CMS
Pacira Pharmaceuticals Incorporated $2.8801/13/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151252195 CMS
Pacira Pharmaceuticals Incorporated $25.3101/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151252197 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $3,623.35 59
PY2020 $4,240.58 60
PY2021 $1,059.37 59
PY2022 $317.77 13
PY2023 $770.34 4
PY2024 $2,741.69 24

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $2,774,310.43 131
PY2024 Recipient $1,401.65 10
PY2024 Principal investigator $1,886,016.65 154
PY2023 Recipient $1,734.07 2
PY2023 Principal investigator $1,613,093.87 174
PY2022 Recipient $7,938.00 2
PY2022 Principal investigator $1,203,947.96 117
PY2021 Recipient $1,793.52 3
PY2021 Principal investigator $874,519.06 78
PY2020 Principal investigator $706,623.45 80
PY2019 Recipient $1,208.55 9
PY2019 Principal investigator $596,855.42 115

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

119 records in PY2022

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AstraZeneca UK Limited $1,585.27 12/31/2022 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Phase 2b Multinational Randomised Double-blind Parallelgroup 24-week Placebo-controlled Study with 28-week Extension to Investigate the Use of Benralizumab in Patients with Moderate to Severe Chronic Spontaneous Urticaria No dispute reported 06/30/2026 914597547
Principal investigator 1 Eli Lilly and Company $163.00 12/29/2022 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY No dispute reported 06/30/2026 917823775
Principal investigator 1 Eli Lilly and Company $14,000.00 12/29/2022 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A PHASE 3, PARALLEL-DESIGN, OPEN-LABEL, RANDOMIZED CONTROL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3209590 ADMINISTERED WEEKLY USING A FIXED DOSE ESCALATION COMPARED TO INSULIN GLARGINE IN INSULIN-NAIVE ADULTS WITH TYPE 2 DIABETES No dispute reported 06/30/2026 917823815
Principal investigator 1 Mylan Specialty L.P. $6,542.77 12/27/2022 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
A Phase 4, Randomized, Double-Blind, Double-Dummy, Parallel Group Study Comparing Improvements in Lung Function in Adults With Severe to Very Severe Chronic Obstructive Pulmonary Disease and Suboptimal Inspiratory Flow Rate Following Once-Daily Treatment Over 12 Weeks With Either Revefenacin Inhalation Solution Delivered via Standard Jet Nebulizer or Tiotropium Delivered via a Dry Powder Inhaler (Spiriva HandiHaler) No dispute reported 06/30/2026 962566451
Principal investigator 1 GRT US Holding, Inc. $3,607.20 12/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AV001 No dispute reported 06/30/2026 890147181
Principal investigator 1 Eli Lilly and Company $14,000.00 12/19/2022 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY No dispute reported 06/30/2026 917825005
Principal investigator 1 GRT US Holding, Inc. $2,635.00 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AV001 No dispute reported 06/30/2026 890147175
Principal investigator 1 GRT US Holding, Inc. $5,000.00 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AV001 No dispute reported 06/30/2026 890147177
Principal investigator 1 ABBVIE INC. $12,430.82 12/14/2022 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) No dispute reported 06/30/2026 889825057
Principal investigator 1 GRT US Holding, Inc. $6,505.20 12/14/2022 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AV001 No dispute reported 06/30/2026 890147171
Principal investigator 1 SANOFI US SERVICES INC. $3,650.00 12/12/2022 Non-covered Recipient Entity
Clinical Research Of West Florida
Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/ REGN3500/ Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 935668667
Principal investigator 1 ABBVIE INC. $8,274.05 12/08/2022 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2) No dispute reported 06/30/2026 889823957
Principal investigator 1 GRT US Holding, Inc. $309.60 12/06/2022 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AV001 No dispute reported 06/30/2026 890147149
Principal investigator 1 GRT US Holding, Inc. $2,611.80 12/01/2022 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AV001 No dispute reported 06/30/2026 890147137
Principal investigator 1 Mylan Specialty L.P. $12,022.02 11/23/2022 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
A Phase 4, Randomized, Double-Blind, Double-Dummy, Parallel Group Study Comparing Improvements in Lung Function in Adults With Severe to Very Severe Chronic Obstructive Pulmonary Disease and Suboptimal Inspiratory Flow Rate Following Once-Daily Treatment Over 12 Weeks With Either Revefenacin Inhalation Solution Delivered via Standard Jet Nebulizer or Tiotropium Delivered via a Dry Powder Inhaler (Spiriva HandiHaler) No dispute reported 06/30/2026 962565527
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,500.00 11/14/2022 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A PHASE 4 MULTICENTER OPEN-LABEL SINGLE-ARM STUDY OF SAFETY TOLERABILITY EFFECTIVENESS AND TREATMENT OPTIMIZATION IN PARTICIPANTS SWITCHING FROM XYREM TO XYWAV FOR THE TREATMENT OF NARCOLEPSY No dispute reported 06/30/2026 950368661
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $5,000.00 11/14/2022 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A PHASE 4 MULTICENTER OPEN-LABEL SINGLE-ARM STUDY OF SAFETY TOLERABILITY EFFECTIVENESS AND TREATMENT OPTIMIZATION IN PARTICIPANTS SWITCHING FROM XYREM TO XYWAV FOR THE TREATMENT OF NARCOLEPSY No dispute reported 06/30/2026 950368663
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,500.00 11/14/2022 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A PHASE 4 MULTICENTER OPEN-LABEL SINGLE-ARM STUDY OF SAFETY TOLERABILITY EFFECTIVENESS AND TREATMENT OPTIMIZATION IN PARTICIPANTS SWITCHING FROM XYREM TO XYWAV FOR THE TREATMENT OF NARCOLEPSY No dispute reported 06/30/2026 950368665
Principal investigator 1 SANOFI US SERVICES INC. $450.00 11/14/2022 Non-covered Recipient Entity
Clinical Research Of West Florida
Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/ REGN3500/ Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 935668660
Principal investigator 1 GRT US Holding, Inc. $7,441.20 11/10/2022 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AV001 No dispute reported 06/30/2026 890147161
Principal investigator 2 UCB SA $12,700.00 11/10/2022 Non-covered Recipient Entity
Clinical Research Of West Florida
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DAPIROLIZUMAB PEGOL IN STUDY PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS No dispute reported 06/30/2026 957715013
Principal investigator 1 ABBVIE INC. $9,659.09 11/09/2022 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) No dispute reported 06/30/2026 889819177
Principal investigator 1 ABBVIE INC. $1,924.50 11/08/2022 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2) No dispute reported 06/30/2026 889818257
Principal investigator 1 ABBVIE INC. $2,500.00 11/03/2022 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate No dispute reported 06/30/2026 889817947
Principal investigator 1 GRT US Holding, Inc. $3,195.00 11/02/2022 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AV001 No dispute reported 06/30/2026 890147139
Principal investigator 1 GRT US Holding, Inc. $2,653.00 11/02/2022 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AV001 No dispute reported 06/30/2026 890147141
Principal investigator 1 GRT US Holding, Inc. $135.00 11/02/2022 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AV001 No dispute reported 06/30/2026 890147143
Principal investigator 1 GRT US Holding, Inc. $4,000.00 11/02/2022 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AV001 No dispute reported 06/30/2026 890147145
Principal investigator 1 Mylan Specialty L.P. $12,146.97 10/27/2022 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
A Phase 4, Randomized, Double-Blind, Double-Dummy, Parallel Group Study Comparing Improvements in Lung Function in Adults With Severe to Very Severe Chronic Obstructive Pulmonary Disease and Suboptimal Inspiratory Flow Rate Following Once-Daily Treatment Over 12 Weeks With Either Revefenacin Inhalation Solution Delivered via Standard Jet Nebulizer or Tiotropium Delivered via a Dry Powder Inhaler (Spiriva HandiHaler) No dispute reported 06/30/2026 962565519
Principal investigator 1 GRT US Holding, Inc. $11,469.60 10/18/2022 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AV001 No dispute reported 06/30/2026 890147179
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $100.00 10/14/2022 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A PHASE 4 MULTICENTER OPEN-LABEL SINGLE-ARM STUDY OF SAFETY TOLERABILITY EFFECTIVENESS AND TREATMENT OPTIMIZATION IN PARTICIPANTS SWITCHING FROM XYREM TO XYWAV FOR THE TREATMENT OF NARCOLEPSY No dispute reported 06/30/2026 950368659
Principal investigator 1 ABBVIE INC. $7,257.60 10/13/2022 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) No dispute reported 06/30/2026 889815369
Principal investigator 1 ABBVIE INC. $3,108.30 10/12/2022 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate No dispute reported 06/30/2026 889814371
Principal investigator 1 GRT US Holding, Inc. $619.20 10/07/2022 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AV001 No dispute reported 06/30/2026 890147151
Principal investigator 1 SANOFI US SERVICES INC. $2,500.00 10/04/2022 Non-covered Recipient Entity
Clinical Research Of West Florida
Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/ REGN3500/ Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 935668627
Principal investigator 1 GRT US Holding, Inc. $6,457.50 09/28/2022 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AV001 No dispute reported 06/30/2026 890147193
Principal investigator 1 ABBVIE INC. $3,100.00 09/22/2022 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) No dispute reported 06/30/2026 889812099
Principal investigator 1 ABBVIE INC. $4,400.00 09/22/2022 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2) No dispute reported 06/30/2026 889812101
Principal investigator 1 GlaxoSmithKline, LLC. $19,184.30 09/22/2022 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A MULTI-CENTRE LONG-TERM EXTENSION STUDY TO ASSESS THE SAFETY AND EFFI No dispute reported 06/30/2026 944035545
Principal investigator 1 GRT US Holding, Inc. $3,195.00 09/14/2022 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AV001 No dispute reported 06/30/2026 890147173
Principal investigator 1 SANOFI US SERVICES INC. $2,350.00 09/12/2022 Non-covered Recipient Entity
Clinical Research Of West Florida
Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/ REGN3500/ Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 935668525
Principal investigator 1 GRT US Holding, Inc. $9,805.50 09/09/2022 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AV001 No dispute reported 06/30/2026 890147157
Principal investigator 1 ABBVIE INC. $13,407.55 09/07/2022 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) No dispute reported 06/30/2026 889808505
Principal investigator 1 Eli Lilly and Company $46,250.00 08/30/2022 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, TWO-ARM, PHASE 2 CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF LY3361237 AS A TREATMENT FOR ADULTS WITH AT LEAST MODERATELY ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS No dispute reported 06/30/2026 917823769
Principal investigator 1 Mylan Specialty L.P. $19,497.96 08/29/2022 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
A Phase 4, Randomized, Double-Blind, Double-Dummy, Parallel Group Study Comparing Improvements in Lung Function in Adults With Severe to Very Severe Chronic Obstructive Pulmonary Disease and Suboptimal Inspiratory Flow Rate Following Once-Daily Treatment Over 12 Weeks With Either Revefenacin Inhalation Solution Delivered via Standard Jet Nebulizer or Tiotropium Delivered via a Dry Powder Inhaler (Spiriva HandiHaler) No dispute reported 06/30/2026 962565523
Principal investigator 1 SANOFI US SERVICES INC. $4,750.00 08/22/2022 Non-covered Recipient Entity
Clinical Research Of West Florida
Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/ REGN3500/ Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 935668533
Principal investigator 1 ABBVIE INC. $1,542.45 08/11/2022 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate No dispute reported 06/30/2026 889805447
Principal investigator 1 ABBVIE INC. $10,033.89 08/10/2022 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) No dispute reported 06/30/2026 889804255
Principal investigator 1 GRT US Holding, Inc. $1,481.40 08/09/2022 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AV001 No dispute reported 06/30/2026 890147153
Principal investigator 1 SANOFI US SERVICES INC. $2,925.00 08/02/2022 Non-covered Recipient Entity
Clinical Research Of West Florida
Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/ REGN3500/ Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 935668493
Principal investigator 1 GRT US Holding, Inc. $3,936.60 07/27/2022 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AV001 No dispute reported 06/30/2026 890147191
Principal investigator 1 ABBVIE INC. $3,000.00 07/26/2022 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) No dispute reported 06/30/2026 889802179
Principal investigator 1 Mylan Specialty L.P. $12,698.53 07/26/2022 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
A Phase 4, Randomized, Double-Blind, Double-Dummy, Parallel Group Study Comparing Improvements in Lung Function in Adults With Severe to Very Severe Chronic Obstructive Pulmonary Disease and Suboptimal Inspiratory Flow Rate Following Once-Daily Treatment Over 12 Weeks With Either Revefenacin Inhalation Solution Delivered via Standard Jet Nebulizer or Tiotropium Delivered via a Dry Powder Inhaler (Spiriva HandiHaler) No dispute reported 06/30/2026 962566339
Principal investigator 1 GRT US Holding, Inc. $2,940.30 07/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AV001 No dispute reported 06/30/2026 890147183
Principal investigator 1 SANOFI US SERVICES INC. $1,950.00 07/18/2022 Non-covered Recipient Entity
Clinical Research Of West Florida
Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/ REGN3500/ Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 935668477
Principal investigator 1 ABBVIE INC. $2,022.55 07/14/2022 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2) No dispute reported 06/30/2026 889800795
Principal investigator 1 ABBVIE INC. $14,349.17 07/13/2022 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) No dispute reported 06/30/2026 889800347
Principal investigator 1 Beckman Coulter, Inc. $4,333.07 07/12/2022 Non-covered Recipient Entity
Clinical Research West Florida, Inc.
HF-04-18 No dispute reported 06/30/2026 937457847
Principal investigator 1 GRT US Holding, Inc. $4,082.40 07/12/2022 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AV001 No dispute reported 06/30/2026 890147163
Principal investigator 1 ABBVIE INC. $1,565.85 07/05/2022 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate No dispute reported 06/30/2026 889798353
Principal investigator 1 GlaxoSmithKline, LLC. $433.20 07/05/2022 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 944035555
Principal investigator 1 Mylan Specialty L.P. $22,216.03 06/20/2022 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
A Phase 4, Randomized, Double-Blind, Double-Dummy, Parallel Group Study Comparing Improvements in Lung Function in Adults With Severe to Very Severe Chronic Obstructive Pulmonary Disease and Suboptimal Inspiratory Flow Rate Following Once-Daily Treatment Over 12 Weeks With Either Revefenacin Inhalation Solution Delivered via Standard Jet Nebulizer or Tiotropium Delivered via a Dry Powder Inhaler (Spiriva HandiHaler) No dispute reported 06/30/2026 962565525
Principal investigator 1 SANOFI US SERVICES INC. $1,150.00 06/13/2022 Non-covered Recipient Entity
Clinical Research Of West Florida
Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/ REGN3500/ Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 935668485
Principal investigator 1 ABBVIE INC. $5,449.85 06/09/2022 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2) No dispute reported 06/30/2026 889794971
Principal investigator 1 ABBVIE INC. $7,223.86 06/09/2022 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) No dispute reported 06/30/2026 889794997
Principal investigator 1 GRT US Holding, Inc. $2,059.20 06/09/2022 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AV001 No dispute reported 06/30/2026 890147155
Principal investigator 1 SANOFI US SERVICES INC. $5,000.00 06/02/2022 Non-covered Recipient Entity
Clinical Research Of West Florida
Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/ REGN3500/ Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 935668357
Principal investigator 1 Eli Lilly and Company $941.00 05/26/2022 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A MASTER PROTOCOL FOR A RANDOMIZED, PLACEBO-CONTROLLED CLINICAL TRIAL OF MULTIPLE INTERVENTIONS FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS No dispute reported 06/30/2026 917820411
Principal investigator 1 AstraZeneca Pharmaceuticals LP $36,800.00 05/25/2022 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
Onset of Effect Questionnaire No dispute reported 06/30/2026 914593011
Principal investigator 1 GRT US Holding, Inc. $309.60 05/25/2022 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AV001 No dispute reported 06/30/2026 890147187
Principal investigator 1 UCB SA $726.50 05/19/2022 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DAPIROLIZUMAB PEGOL IN STUDY PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS No dispute reported 06/30/2026 957715153
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $2,828.52 05/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A PHASE 4 MULTICENTER OPEN-LABEL SINGLE-ARM STUDY OF SAFETY TOLERABILITY EFFECTIVENESS AND TREATMENT OPTIMIZATION IN PARTICIPANTS SWITCHING FROM XYREM TO XYWAV FOR THE TREATMENT OF NARCOLEPSY No dispute reported 06/30/2026 950368657
Principal investigator 1 SANOFI US SERVICES INC. $3,450.00 05/16/2022 Non-covered Recipient Entity
Clinical Research Of West Florida
Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/ REGN3500/ Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 935668317
Principal investigator 2 UCB SA $124.34 05/13/2022 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND TOLERABILITY OF DAPIROLIZUMAB PEGOL TREATMENT IN STUDY PARTICIPANTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS No dispute reported 06/30/2026 957715655
Principal investigator 1 ABBVIE INC. $3,446.30 05/12/2022 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate No dispute reported 06/30/2026 889792127
Principal investigator 1 GRT US Holding, Inc. $5,306.00 05/12/2022 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AV001 No dispute reported 06/30/2026 890147165
Principal investigator 1 GRT US Holding, Inc. $270.00 05/12/2022 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AV001 No dispute reported 06/30/2026 890147167
Principal investigator 1 ABBVIE INC. $5,803.66 05/10/2022 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) No dispute reported 06/30/2026 889790797
Principal investigator 1 Mylan Specialty L.P. $19,052.70 05/10/2022 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
A Phase 4, Randomized, Double-Blind, Double-Dummy, Parallel Group Study Comparing Improvements in Lung Function in Adults With Severe to Very Severe Chronic Obstructive Pulmonary Disease and Suboptimal Inspiratory Flow Rate Following Once-Daily Treatment Over 12 Weeks With Either Revefenacin Inhalation Solution Delivered via Standard Jet Nebulizer or Tiotropium Delivered via a Dry Powder Inhaler (Spiriva HandiHaler) No dispute reported 06/30/2026 962565517
Principal investigator 1 Mylan Specialty L.P. $6,950.00 05/09/2022 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
A Phase 4, Randomized, Double-Blind, Double-Dummy, Parallel Group Study Comparing Improvements in Lung Function in Adults With Severe to Very Severe Chronic Obstructive Pulmonary Disease and Suboptimal Inspiratory Flow Rate Following Once-Daily Treatment Over 12 Weeks With Either Revefenacin Inhalation Solution Delivered via Standard Jet Nebulizer or Tiotropium Delivered via a Dry Powder Inhaler (Spiriva HandiHaler) No dispute reported 06/30/2026 962565515
Principal investigator 1 ABBVIE INC. $1,403.55 05/05/2022 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2) No dispute reported 06/30/2026 889790411
Principal investigator 1 GRT US Holding, Inc. $309.60 05/05/2022 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AV001 No dispute reported 06/30/2026 890147147
Recipient Eli Lilly and Company $447.00 04/29/2022 Covered Recipient Physician EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY VERSUS PLACEBO AFTER AN INTENSIVE LIFESTYLE PROGRAM IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES: A RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED TRIAL (SURMOUNT-3) No dispute reported 06/30/2026 917813533
Principal investigator 1 ABBVIE INC. $2,000.00 04/27/2022 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) No dispute reported 06/30/2026 889788721
Principal investigator 1 GRT US Holding, Inc. $552.60 04/27/2022 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AV001 No dispute reported 06/30/2026 890147189
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $1,131.10 04/26/2022 Non-covered Recipient Entity
Clinical Research Of West Florida
A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of BMS-986165 in Subjects with Moderate to Severe Crohn's Disease No dispute reported 06/30/2026 933187221
Principal investigator 1 Eli Lilly and Company $2,327.00 04/26/2022 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, TWO-ARM, PHASE 2 CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF LY3361237 AS A TREATMENT FOR ADULTS WITH AT LEAST MODERATELY ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS No dispute reported 06/30/2026 917823169
Principal investigator 1 Eli Lilly and Company $40,000.00 04/25/2022 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A MASTER PROTOCOL FOR A RANDOMIZED, PLACEBO-CONTROLLED CLINICAL TRIAL OF MULTIPLE INTERVENTIONS FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS No dispute reported 06/30/2026 917825003
Principal investigator 1 Mylan Specialty L.P. $13,759.85 04/15/2022 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
A Phase 4, Randomized, Double-Blind, Double-Dummy, Parallel Group Study Comparing Improvements in Lung Function in Adults With Severe to Very Severe Chronic Obstructive Pulmonary Disease and Suboptimal Inspiratory Flow Rate Following Once-Daily Treatment Over 12 Weeks With Either Revefenacin Inhalation Solution Delivered via Standard Jet Nebulizer or Tiotropium Delivered via a Dry Powder Inhaler (Spiriva HandiHaler) No dispute reported 06/30/2026 962566647
Principal investigator 1 GRT US Holding, Inc. $4,720.50 04/13/2022 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AV001 No dispute reported 06/30/2026 890147169
Principal investigator 1 SANOFI US SERVICES INC. $3,650.00 04/11/2022 Non-covered Recipient Entity
Clinical Research Of West Florida
Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/ REGN3500/ Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 935668261
Principal investigator 1 ABBVIE INC. $17,994.68 04/06/2022 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) No dispute reported 06/30/2026 889783637
Principal investigator 1 GRT US Holding, Inc. $309.60 03/31/2022 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AV001 No dispute reported 06/30/2026 890147195
Principal investigator 1 SANOFI US SERVICES INC. $1,500.00 03/21/2022 Non-covered Recipient Entity
Clinical Research Of West Florida
Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/ REGN3500/ Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 935668325
Principal investigator 1 ABBVIE INC. $3,478.10 03/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2) No dispute reported 06/30/2026 889782093
Principal investigator 1 SANOFI US SERVICES INC. $2,850.00 03/14/2022 Non-covered Recipient Entity
Clinical Research Of West Florida
Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/ REGN3500/ Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 935668341
Principal investigator 1 GRT US Holding, Inc. $552.60 03/10/2022 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AV001 No dispute reported 06/30/2026 890147159
Principal investigator 1 AstraZeneca UK Limited $4,000.00 03/09/2022 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Phase 2b Multinational Randomised Double-blind Parallelgroup 24-week Placebo-controlled Study with 28-week Extension to Investigate the Use of Benralizumab in Patients with Moderate to Severe Chronic Spontaneous Urticaria No dispute reported 06/30/2026 914593603
Principal investigator 1 Mylan Specialty L.P. $16,019.77 03/09/2022 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
A Phase 4, Randomized, Double-Blind, Double-Dummy, Parallel Group Study Comparing Improvements in Lung Function in Adults With Severe to Very Severe Chronic Obstructive Pulmonary Disease and Suboptimal Inspiratory Flow Rate Following Once-Daily Treatment Over 12 Weeks With Either Revefenacin Inhalation Solution Delivered via Standard Jet Nebulizer or Tiotropium Delivered via a Dry Powder Inhaler (Spiriva HandiHaler) No dispute reported 06/30/2026 962566279
Principal investigator 1 ABBVIE INC. $3,100.28 03/08/2022 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) No dispute reported 06/30/2026 889779937
Principal investigator 1 Mylan Specialty L.P. $19,194.00 03/04/2022 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
A Phase 4, Randomized, Double-Blind, Double-Dummy, Parallel Group Study Comparing Improvements in Lung Function in Adults With Severe to Very Severe Chronic Obstructive Pulmonary Disease and Suboptimal Inspiratory Flow Rate Following Once-Daily Treatment Over 12 Weeks With Either Revefenacin Inhalation Solution Delivered via Standard Jet Nebulizer or Tiotropium Delivered via a Dry Powder Inhaler (Spiriva HandiHaler) No dispute reported 06/30/2026 962565449
Principal investigator 1 Eli Lilly and Company $67,680.00 03/01/2022 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE No dispute reported 06/30/2026 917823161
Principal investigator 1 ABBVIE INC. $5,000.00 02/24/2022 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
Rheumatoid Arthritis (RA) is an inflammatory disease of the joints causing pain, stiffness, swelling and loss of joint function. This study evaluates how safe and effective ABBV-154 is in participants treated for moderately to severely active RA. Adverse events and change in the disease activity will be assessed. No dispute reported 06/30/2026 889778481
Principal investigator 1 GRT US Holding, Inc. $4,720.50 02/23/2022 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AV001 No dispute reported 06/30/2026 890147185
Principal investigator 1 SANOFI US SERVICES INC. $1,600.00 02/22/2022 Non-covered Recipient Entity
Clinical Research Of West Florida
Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/ REGN3500/ Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 935668180
Principal investigator 1 ABBVIE INC. $3,239.46 02/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate (SELECT-COMPARE) No dispute reported 06/30/2026 889777921
Principal investigator 1 ABBVIE INC. $2,022.55 02/15/2022 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Study to Evaluate Upadacitinib in Adolescent and Adult Subjects With Moderate to Severe Atopic Dermatitis (Measure Up 2) No dispute reported 06/30/2026 889777129
Principal investigator 1 Mylan Specialty L.P. $4,738.50 02/14/2022 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
A Phase 4, Randomized, Double-Blind, Double-Dummy, Parallel Group Study Comparing Improvements in Lung Function in Adults With Severe to Very Severe Chronic Obstructive Pulmonary Disease and Suboptimal Inspiratory Flow Rate Following Once-Daily Treatment Over 12 Weeks With Either Revefenacin Inhalation Solution Delivered via Standard Jet Nebulizer or Tiotropium Delivered via a Dry Powder Inhaler (Spiriva HandiHaler) No dispute reported 06/30/2026 962565441
Principal investigator 1 ABBVIE INC. $2,045.00 02/10/2022 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Study to Evaluate Upadacitinib in Adolescent and Adult Subjects With Moderate to Severe Atopic Dermatitis (Measure Up 2) No dispute reported 06/30/2026 889776631
Principal investigator 1 ABBVIE INC. $5,821.20 02/10/2022 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate (SELECT-COMPARE) No dispute reported 06/30/2026 889776659
Recipient Eli Lilly and Company $7,491.00 02/08/2022 Covered Recipient Physician A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE No dispute reported 06/30/2026 917815225
Principal investigator 1 SANOFI US SERVICES INC. $6,950.00 02/03/2022 Non-covered Recipient Entity
Clinical Research Of West Florida
Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/ REGN3500/ Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 935668171
Principal investigator 1 Eli Lilly and Company $2,330.00 01/31/2022 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY VERSUS PLACEBO AFTER AN INTENSIVE LIFESTYLE PROGRAM IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES: A RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED TRIAL (SURMOUNT-3) No dispute reported 06/30/2026 917823167
Principal investigator 1 Amgen Inc. $282.33 01/26/2022 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLOR
Ph4 Otezla in oligoarticular PsA (FOREMOST)/KEG No dispute reported 06/30/2026 942843505
Principal investigator 1 Novartis Pharmaceuticals Corporation $301,885.32 01/20/2022 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
AN OPEN LABEL SINGLE ARM MULTI CENTER EXTENSION STUDY EVALUATING LONG TERM SAFETY TOLERABILITY AND EFFECTIVENESS OF OFATUMUMAB IN SUBJECTS WITH RELAPSING MULTIPLE SCLEROSIS No dispute reported 06/30/2026 909391785
Principal investigator 1 ABBVIE INC. $7,000.00 01/13/2022 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate (SELECT-COMPARE) No dispute reported 06/30/2026 889773953
Principal investigator 1 ABBVIE INC. $5,495.90 01/12/2022 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Study to Evaluate Upadacitinib in Adolescent and Adult Subjects With Moderate to Severe Atopic Dermatitis (Measure Up 2) No dispute reported 06/30/2026 889773315
Principal investigator 2 UCB SA $28,017.00 01/06/2022 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DAPIROLIZUMAB PEGOL IN STUDY PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS No dispute reported 06/30/2026 957714263
Principal investigator 1 Eli Lilly and Company $104,271.00 01/04/2022 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY VERSUS PLACEBO AFTER AN INTENSIVE LIFESTYLE PROGRAM IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES: A RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED TRIAL (SURMOUNT-3) No dispute reported 06/30/2026 917820407